Why the study?
It remained unclear whether long-term survival is superior following transcatheter aortic valve implantation compared with surgical aortic valve replacement.
Does transcatheter aortic valve implantation (TAVI) reduce long-term all-cause mortality compared to surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis?
Does transcatheter aortic valve implantation (TAVI) reduce long-term all-cause mortality compared to surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis?
While observational propensity-matched data suggest higher long-term mortality with TAVI compared to SAVR at ≥5 years, randomized controlled trials show no significant difference between the two strategies.
INTRODUCTION: It remains unclear whether long-term survival is superior following transcatheter aortic valve implantation (TAVI) than following surgical aortic valve replacement (SAVR). We performed a meta-analysis of mortality with ≥5-year follow-up in randomized controlled trials (RCTs) and propensity-score matched (PSM) studies of TAVI versus SAVR. EVIDENCE ACQUISITION: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through March 2019. Eligible studies were RCTs or PSM studies of TAVI versus SAVR enrolling patients with severe aortic stenosis and reporting all-cause mortality with ≥5-year follow-up as an outcome. A hazard ratio of mortality for TAVI versus SAVR was extracted from each individual study. EVIDENCE SYNTHESIS: Our search identified 3 RCTs and 7 PSM studies enrolling 5498 patients. A pooled analysis of all 10 studies demonstrated a statistically significant 38% increase in mortality with TAVI relative to SAVR. A subgroup meta-analysis showed no statistically significant difference between TAVI and AVR in RCTs and a statistically significant 68% increase with TAVI relative to SAVR in PSM studies. CONCLUSIONS: On the basis of a meta-analysis of 7 PSM studies, TAVI is associated with greater all-cause mortality with ≥5-year follow-up than SAVR. However, another meta-analysis of 3 RCTs suggests no difference in mortality between TAVI and SAVR.
No takes yet. Share an insight, caveat, or question.
Takagi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: